Structure and function analysis of CaMdr1p, a major facilitator superfamily antifungal efflux transporter protein of Candida albicans: identification of amino acid residues critical for drug/H<SUP>+</SUP> transport by Pasrija, Ritu et al.
EUKARYOTIC CELL, Mar. 2007, p. 443–453 Vol. 6, No. 3
1535-9778/07/$08.000 doi:10.1128/EC.00315-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Structure and Function Analysis of CaMdr1p, a Major Facilitator
Superfamily Antifungal Efflux Transporter Protein of Candida albicans:
Identification of Amino Acid Residues Critical for
Drug/H Transport†
Ritu Pasrija, Dibyendu Banerjee, and Rajendra Prasad*
Membrane Biology Lab, School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
Received 3 October 2006/Accepted 21 December 2006
We have cloned and overexpressed multidrug transporter CaMdr1p as a green fluorescent protein-
tagged protein to show its capability to extrude drug substrates. The drug extrusion was sensitive to pH
and energy inhibitors and displayed selective substrate specificity. CaMdr1p has a unique and conserved
antiporter motif, also called motif C [G(X6)G(X3)GP(X2)GP(X2)G], in its transmembrane segment 5
(TMS 5). Alanine scanning of all the amino acids of the TMS 5 by site-directed mutagenesis highlighted
the importance of the motif, as well as that of other residues of TMS 5, in drug transport. The mutant
variants of TMS 5 were placed in four different categories. The first category had four residues, G244,
G251, G255, and G259, which are part of the conserved motif C, and their substitution with alanine
resulted in increased sensitivity to drugs and displayed impaired efflux of drugs. Interestingly, first
category mutants, when replaced with leucine, resulted in more dramatic loss of drug resistance and efflux.
Notwithstanding the location in the core motif, the second category included residues which are part of the
motif, such as P260, and those which were not part of the motif, such as L245, W248, P256, and F262,
whose substitution with alanine resulted in a severe loss of drug resistance and efflux. The third category
included G263, which is a part of motif C, but unlike other conserved glycines, its replacement with alanine
or leucine showed no change in the phenotype. The replacement of the remaining 11 residues of the fourth
category did not result in any change. The putative helical wheel projection showed clustering of func-
tionally critical residues to one side and thus suggests an asymmetric nature of TMS 5.
In recent years, incidences of acquired resistance to azoles in
the fungal pathogen Candida albicans, have increased consid-
erably, which poses serious problems in successful chemother-
apy of candidiasis. Current evidence suggests that Candida
acquires azole resistance by employing multiple mechanisms
that include (i) failure of drug accumulation mediated by ex-
trusion pump proteins such as Cdr1p and Cdr2p, belonging to
ATP binding cassette (ABC), and CaMdr1p, belonging to ma-
jor facilitator superfamilies (MFS), (ii) alterations in the azole
target protein Erg11p, and (iii) up regulation of the ERG11
gene (11, 13, 16).
The multidrug transporters of Candida belonging to the
ABC superfamily have been studied extensively. Typically, the
predicted topology of Cdr1p and Cdr2p exhibits characteristic
features of an ABC transporter; it contains two highly hydro-
phobic transmembrane domains and two cytoplasm-localized
nucleotide binding domains. Each transmembrane domain is
comprised of six transmembrane segments (TMS) which are
envisaged to confer substrate specificity (22). The nature of
Cdr1p and Cdr2p substrates varies enormously, as it includes
structurally unrelated compounds such as azoles, lipids, and
steroids (10, 26). The structure and function of MFS multidrug
transporter CaMdr1p of C. albicans is more poorly understood
than ABC drug exporters.
The MFS consists of membrane transport proteins from
bacteria to higher eukaryotes involved in symport, antiport, or
uniport of various substrates (2, 5, 21, 24, 29). One major
cluster of this superfamily consists of proton motive force-
dependent drug efflux proteins (14). Bacterial MFS drug trans-
porters are antiporters, which have a unique antiporter motif,
also called motif C [G(X8)G(X3)GP(X2)GG], necessary for
the drug/H antiport activity (5, 15). Independent of antiporter’s
substrate specificities, the antiporter motif in the predicted
TMS 5 is conserved in all of the functionally related subgroups
in bacteria and plants (14, 25, 29). Although MFS drug export-
ers in yeast also possess the antiporter motif, its relevance
remains to be established. This motif C also has a repetitive
GXXXG stretch, which is thought to be important in proper
helix packing and dimerization in the ABCG2 transporter of
humans (15). Multiple-sequence analysis of the MFS trans-
porters reveals that proteins within this family share greater
similarity between their N-terminal halves than in their C-
terminal halves, and it is assumed that the later half is respon-
sible for substrate recognition (14). Additionally, the MFS
drug antiporter proteins possess many other conserved resi-
dues scattered throughout the length of the protein, for exam-
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ple, motifs A and B are conserved throughout the MFS, while
motif C is conserved in only 12- and 14-TMS subfamilies (14).
The CaMdr1p (NCBI database accession no. X53823) of C.
albicans (formerly BENr, benomyl resistance) is a 564-amino-
acid protein with 12 TMSs (1, 4, 6, 9). Based on sequence
homology, CaMdr1p is a putative antiporter, with an anti-
porter motif in TMS 5 [G(X6)G(X3)GP(X2)GP(X2)G] (14).
Keeping in view the relevance of the MFS multidrug trans-
porter CaMdr1p in azole resistance in Candida, in this study we
have examined this protein in terms of its structure and function.
For this, we have overexpressed CaMdr1p as a green fluorescent
protein (GFP)-tagged protein in a heterologous system. To eval-
uate the residues of TMS 5 that potentially contribute to drug/H
transport, we did alanine scanning of all 21 amino acids of TMS
5 by site-directed mutagenesis. Our results highlighted the impor-
tance of the mutant variants of TMS 5, which became hypersen-
sitive to different classes of drugs, with severely impaired efflux
activity. Our results for the first time support the prediction that
MFS CaMdr1p of C. albicans functions as a drug/H antiporter,
wherein amino acid residues within conserved motifs as well as
outside are crucial for its functioning.
MATERIALS AND METHODS
Materials. Media chemicals were obtained from Difco (BD Biosciences) and
HiMedia (Mumbai, India). The drugs cycloheximide, 4-nitroquinoline, metho-
trexate, cerulenin, and protease inhibitors (phenylmethylsulfonyl fluoride, leu-
peptin, pepstatin A, and aprotinin) were obtained from Sigma Chemical Co. (St.
Louis, MO). Anti-GFP monoclonal antibody was purchased from BD Bio-
sciences Clontech, Palo Alto, CA. [3H]fluconazole ([3H]FLC) was custom pre-
pared, and [3H]methotrexate ([3H]MTX) was procured from Amersham Bio-
sciences, United Kingdom. Ranbaxy Laboratories (New Delhi, India) kindly
provided fluconazole.
Bacterial and yeast strains and growth media. Plasmids were maintained in
Escherichia coli DH5. E. coli was cultured in Luria-Bertani medium (Difco, BD
Biosciences) to which ampicillin was added (100 g/ml). The Saccharomyces
cerevisiae strain used was AD1-8u (MATa pdr1-3 his1 ura3 yor1:: hisG
snq2::hisG pdr5::hisG pdr10::hisG pdr11::hisG ycf1::hisG pdr3::hisG
pdr15::hisG), provided by Richard D. Cannon, University of Otago, Dunedin,
New Zealand. The yeast strains used in this study are listed in Table S1 in the
supplemental material. AD1-8u, RPCaMDR1-GFP (AD1-8u derivative
expressing CaMDR1-GFP), RPCaMDR1 (AD1-8u derivative expressing
CaMDR1), and the mutants were grown in yeast extract-peptone-dextrose
(YEPD) broth (Bio101, Vista, CA) or in SD Ura dropout media (0.67% yeast
nitrogen base, 0.2% dropout mix, and 2% glucose; Difco). For agar plates, 2.5%
(wt/vol) Bacto agar (Difco, BD Biosciences) was added to the medium.
Overexpression of CaMDR1-GFP and its integration at the PDR5 locus. For
overexpressing and tagging GFP at the C-terminal end of the CaMDR1 open
reading frame (ORF), the CaMDR1 ORF was amplified with primers having the
SpeI restriction site, primers CaMdr1-F (5-ACGCGTCGACGGACTAGTTA
GAACTTCACAATGCATTACAG-3) and GFP-R (5-ACGCGTCGACGGA
CTAGTTTATTTGTATAGTTCATCCA-3) (the SpeI site is underlined), and
the PCR product was digested with SpeI and cloned into plasmid pSK-
PDR5PPUS (Fig. 1A) (12). Correct orientation of the CaMDR1 and GFP ORF
was confirmed by restriction enzyme and sequencing. The cloned and sequenced
plasmid was named pRP-CaMDR1-GFP, linearized with XbaI, and used to
transform S. cerevisiae strain AD1-8u by the lithium acetate transformation
protocol (22) to get strain RPCaMDR1-GFP. The integration of plasmid
pRPCaMDR1-GFP was confirmed by Southern analysis (data not shown).
Proper expression and targeting of the protein was confirmed with Northern and
Western analysis as well (Fig. 1B and C, respectively).
Site directed mutagenesis of pCaMDR1-GFP and generation of transfor-
mants. All site-directed mutageneses were carried out using a site-directed
mutagenesis kit (Stratagene, La Jolla, CA) as previously described (22). The
mutations were introduced into plasmid pRPCaMDR1-GFP according to the
manufacturer’s instructions, and the desired nucleotide sequence alterations
were confirmed by DNA sequencing of the ORF. The primers used for the
purpose are listed in Table S2 in the supplemental material. The mutated plas-
mid, after being linearized with XbaI, was used to transform AD1-8u cells for
uracil prototrophy by the lithium acetate transformation protocol (22). Integra-
tion was confirmed with Southern blot analysis.
Preparation of plasma membrane proteins and immunodetection of the
CaMDR1 and its mutant. Purified PM fractions of yeast cells were prepared as
described previously (22). The PM protein concentration was determined by
bicinchoninic acid assay using bovine serum albumin as the standard. For West-
ern blots, membranes were incubated with a 1:5,000 dilution of anti-GFP anti-
body, or a 1:1,000 dilution of anti-Pma1p (plasma membrane ATPase) antibody.
Immunoreactivity was detected using horseradish peroxidase-labeled antibody
with a dilution of 1:5,000 using the enhanced chemiluminescence assay system
(ECL kit; Amersham) (22).
Confocal microscopy. The cells were grown to late log phase in SD-ura
medium, except for AD1-8u, where uridine (0.02%) was added to the SD-ura
medium. The cells were then washed and resuspended in an appropriate volume
of 50 mM HEPES, pH 7.0. The cells were placed on glass slides and then imaged
under an oil immersion objective at 100 magnification on a confocal micro-
scope (Radiance 2100, AGR, 3Q/BLD; Bio-Rad, United Kingdom) (22).
Drug susceptibility assay. Drug susceptibilities of yeast strains were measured
by two independent methods: microdilution assay and spot assay. The MIC80s for
the strains were determined with a broth microdilution method as described
previously (11, 16). For spot assay, 5-l samples of fivefold serial dilutions of
each yeast culture (each with cells suspended in normal saline to an optical
density at 600 nm of 0.1) were spotted onto YEPD plates in the absence (control)
or in the presence of the drugs (11, 16).
Drug transport. Accumulation of [3H]MTX (specific activity, 8.60 Ci/mmol)
and [3H]FLC (specific activity, 19 Ci/mmol) was determined essentially by the
protocol described previously (11, 16). For accumulation assays, 25 M [3H]MTX
and 100 nM [3H]FLC were routinely used. To see the effect of inhibitors on accu-
mulation, different inhibitors were added 10 min before the commencement of the
transport. Different inhibitors used included sodium azide (10 mM), sodium or-
thovanadate (1 mM), carbonyl cyanide m-chlorophenylhydrazone (CCCP) (100
M), sodium arsenate (1 mM), and N-ethylmaleimide (NEM) (1 mM) (9). The
concentrations of inhibitors used were not toxic to cells, and the effects observed
were purely due to their metabolic effect. For competition, [3H]MTX was used at a
final concentration of 25 M, and a fivefold concentration for each substrate was
used (125 M) for competition between MTX and various substrates (9).
For efflux measurements, a 5% yeast cell suspension (2.5 108 cells ml1) was
incubated with [3H]MTX at pH 7.4 for 30 min in the presence of CCCP (100 )
to allow accumulation of drug by passive diffusion. The cells were pelleted and
resuspended in MES buffer of indicated pH to initiate the efflux. An aliquot of
100 l was taken at regular intervals and filtered on a 0.45-m filter disk
(Millipore; India). The cells were washed twice with 3 ml MES-Tris buffer, and
the concentration of drug trapped within the cells was measured by counting the
filter disks in a liquid scintillation counter (Packard).
RESULTS
Overexpressed CaMdr1p-GFP is properly surface localized.
CaMdr1p has recently been overexpressed in C. albicans
cells (7). However, to functionally characterize CaMdr1p, in
this study, we have overexpressed it in a heterologous sys-
tem. For this, we have cloned the CaMdr1p-GFP ORF in
the plasmid pSK-PDR5PPUS (12) and overexpressed it by
integrating it at the PDR5 locus downstream from the PDR5
promoter in the S. cerevisiae strain AD1-8u (12). The host
AD1-8u was derived from a strain containing the pdr1-3
gene with a gain-of-function mutation in the transcription
factor Pdr1p, resulting in constitutive hyperinduction of the
PDR5 promoter (Fig. 1A) (12). Single-copy integration at
the PDR5 promoter was confirmed by Southern hybridiza-
tion (data not shown). The wild-type CaMdr1p-GFP was
transcribed (Fig. 1B), expressed, and properly targeted to
the PM, as evident from the Western blot analysis of the PM
fraction of cells (Fig. 1C). Expression and localization were
also confirmed by confocal microscopy and fluorescence-
activated cell sorter (FACS) analysis (Fig. 1A; see Fig. 6B).
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Overexpressed CaMdr1p-GFP confers drug resistance. We
examined the drug sensitivities of the cells overexpressing wild-
type CaMdr1p-GFP (RPCaMDR1-GFP) by two independent
drug susceptibility methods, viz., microdilution and spot assays.
The microdilution assay revealed that the host strain (AD1-
8u) as expected, was hypersensitive to all of the tested drugs
when compared to the growth control (without drug) (see
Table S3 in the supplemental material). On the contrary, cells
expressing the wild-type CaMdr1p-GFP (RPCaMDR1-GFP)
were able to tolerate the same concentrations of the drugs.
Compared to the host strain (AD1-8u), MIC80s (MIC for
80% inhibition in growth) for the RPCaMDR1-GFP strain
FIG. 1. (A) Strategy showing the cloning and integration of CaMDR1 as CaMDR1-GFP at the PDR5 locus in the overexpression strain of S.
cerevisiae AD1-8u, derived from a pdr1-3 mutant strain with a gain-of-function mutation in the transcription factor Pdr1p, resulting in constitutive
hyperinduction of the PDR5 promoter. (B) Expression of the C. albicans CaMDR1 mRNA in S. cerevisiae strain AD1-8u and RPCaMDR1-GFP.
Total RNA (30 g) from the parental strain, AD1-8u, and RPCaMDR1-GFP was hybridized with a mixture of [-32P]dATP-labeled C. albicans
CaMDR1 probe. The lower part of the panel shows a loading control to indicate equal loading. (C) Immunodetection of CaMdr1p in the PM of
strains AD1-8u(control) and RPCaMDR1-GFP. The Western blot analyses were done with anti-GFP monoclonal antibody. The purity of the PM
fraction was assessed by using anti-Pma1p polyclonal antibody. Confocal pictures of the S. cerevisiae cells expressing GFP-tagged wild-type
CaMDR1. The cells were viewed directly on a glass slide with a 100 oil immersion objective on a Bio-Rad confocal microscope. (D) Spot test
showing that CaMDR1 (untagged, without GFP) and CaMDR1-GFP mediated resistance for various drugs. Cells were spotted on YEPD plates
in the absence of drug (control) and in presence of the following drugs: FLC (0.17 g/ml), CYH (0.2 g/ml), CER (3 g/ml), 4-NQO (0.2 g/ml),
and MTX (65 g/ml).
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were considerably higher (MIC80 of 16 g/ml for FLC, 0.5
g/ml for cycloheximide [CYH], 8 g/ml for cerulenin [CER],
1 g/ml for 4-nitroquinoline [4-NQO], and 128 g/ml for
MTX) (Fig. 1D). The spot assays confirmed the microdilution
results (Fig. 1D; see Table S3 in the supplemental material).
The CaMdr1p-GFP chimeric protein was able to confer drug
resistance similar to the untagged protein CaMdr1p, indicating
that GFP tagging does not affect its ability to function (Fig. 1D;
see Table S3 in the supplemental material). In the following
experiments, we examined the functions of the RPCaMdr1p-
GFP.
CaMdr1p effluxes methotrexate and fluconazole. For
checking the ability of drug extrusion by the overexpressed
CaMdr1p, we measured the net intracellular accumulated
levels of two drug substrates, [3H]MTX and [3H]FLC in
RPCaMDR1-GFP cells (Fig. 2A and B). An increased or
decreased level of accumulation of the drug, at a given point
of time, implies its reduced or enhanced efflux, respectively.
It is apparent from Fig. 2A and B that, compared to the host
(AD1-8u) cells, the accumulation of [3H]MTX and [3H]FLC
was considerably reduced (more efflux) in cells expressing
CaMdr1p-GFP-tagged protein.
Efflux is sensitive to different inhibitors. We observed
that the accumulation of [3H]MTX and [3H]FLC was sen-
sitive to different energy inhibitors such as sodium azide, so-
dium orthovanadate, CCCP, and sodium arsenate (Fig. 2A and
B). The accumulation of [3H]MTX and [3H]FLC was increased
in the presence of these inhibitors, implying reduction in efflux.
The sensitivity of [3H]MTX and [3H]FLC accumulation, par-
ticularly to proton conductor CCCP, suggests that CaMdr1p
function is sensitive to pH and may function as a H anti-
porter. Unlike the efflux of drugs mediated by ABC transporter
Cdr1p (8), the efflux mediated by MFS CaMdr1p was insensi-
tive to the SH blocker NEM.
Efflux of MTX and FLC is pH dependent. To confirm that
CaMdr1p is a putative drug/H transporter, we monitored
the efflux of [3H]MTX and [3H]FLC by exposing cells to
buffers with different pH values (Fig. 3A and B, respec-
FIG. 2. Functional characterization of the RPCaMdr1p-GFP and effect of different inhibitors on accumulation of radiolabeled drugs. [3H]MTX
(A) and [3H]FLC (B) accumulation in RPCaMDR1-GFP cells and host strain AD1-8u (control). Effect of different inhibitors on accumulation
of [3H]MTX (A) and [3H]FLC (B) in the RPCaMdr1p-GFP strain was monitored as described in Materials and Methods. Different inhibitors were
added to various cells 10 min prior to the commencement of transport. Different inhibitors used included sodium azide (10 mM), sodium
orthovanadate (1 mM), CCCP (100 M), sodium arsenate (1 mM), and NEM (1 mM). AD1-8u is shown as the control. The values plotted are
from 10 min after commencement of transport. The results are the means 	 standard deviations from three independent experiments.
FIG. 3. Effect of pH on [3H]MTX and [3H]FLC efflux. The efflux of [3H]MTX (A) and [3H]FLC (B) was monitored by exposing cells to different
pH buffers. In a typical experiment, RPCaMdr1p-GFP cells were treated with CCCP (100 M) for 10 min and were then allowed to accumulate
[3H]MTX for 30 min. These cells were then rapidly pelleted and resuspended in buffers of different pH values. The accumulation of [3H]MTX and
[3H]FLC was measured at rapid succession, as detailed in Materials and Methods. The values plotted are from 10 min after commencement of
efflux. The results are the means 	 standard deviations from three independent experiments.
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tively). In a typical experiment, cells expressing wild-type
CaMdr1p-GFP were treated with proton conductor CCCP
(100 ) and were allowed to accumulate [3H]MTX and
[3H]FLC for up to 30 min. These cells were then rapidly
pelleted and resuspended in buffers of different pH values to
initiate the efflux of accumulated drug against pH gradient.
The efflux of the drug was measured in rapid succession, as
detailed in Materials and Methods. Our results revealed
that MTX efflux is very sensitive to pH (Fig. 3A); for exam-
ple, RPCaMDR1-GFP cells exposed to acidic pH (3.5 to
5.5) showed maximum efflux (lower accumulation) of the
drug. No such pH effect was observed with the host strain
AD1-8u, which did not show any significant efflux of the
drugs (Fig. 3A and B). The efflux of [3H]FLC mediated by
CaMdr1p was also pH sensitive, which was similar to
[3H]MTX and maximum at acidic pH (3.5 to 5.5) (Fig. 3B).
It should be pointed out that ABC drug transporter Cdr1p
of C. albicans, when expressed in S. cerevisiae strain AD1-
8u, could also extrude FLC but at a pH optimum of 7.5
(data not shown).
CaMdr1p harbors conserved drug/H antiporter domain.
The alignment of TMS 5 sequence of CaMdr1p with other
MFS transporters revealed extensive conservation of the
amino acids (Fig. 4C). Notably, all five glycines of CaMdr1p
are conserved in other MFS transporters (Fig. 4C). Consider-
ing the fact that, irrespective of the differences in substrate
specificities among MFS antiporters, a great level of conserva-
tion of amino acid exists in motif C, we analyzed the functional
significance of this motif in drug transport by alanine scanning
of the entire TMS 5 of CaMdr1p. The TMS 5 sequence was
deduced by taking the consensus sequence from the various
bioinformatic programs, including HMMTOP, SOSUI,
TMHMM, and TopPred programs (18–20, 27, 28).
For alanine scanning of TMS 5, we employed a site-directed
mutagenesis approach with mutagenic oligonucleotides (see
Table S2 in the supplemental material) where all the amino
acids of the TMS 5 were substituted to neutral alanine. To
avoid the introduction of new side chains, the three existing
alanines in TMS 5 (A246, A247, and A252) were replaced with
glycine, while 5 glycines (G244, G251, G255, G259, and G263)
were replaced with alanine as well as with long-side-chain
amino acid leucine. All 26 mutant variants of CaMdr1p-GFP
were stably overexpressed as GFP-tagged variants in a heter-
ologous system, as described in Materials and Methods, and
designated as shown in Table S1 in the supplemental material.
Single-copy integration was confirmed with Southern blot anal-
ysis (data not shown).
Conserved TMS 5 residue substitution results in hypersen-
sitive cells. Confirmed positive mutants were screened for
their sensitivity to different substrates by two independent
FIG. 4. (A) Predicted topology of the CaMDR1 with 12 transmembrane segments. The TMS 5 is circled to show the location of the antiporter
motif in the protein. (B) The putative TMS 5 is magnified to show the amino acid residues of TMS 5. (C) Alignment of the protein sequences of
the C. albicans antiporter CaMDR1 TMS 5 with the other fungal and bacterial drug antiporters, showing the presence of the unique and conserved
antiporter motif. The amino acid sequences of TMS 5 of CaMdr1p between positions 243 and 263 (boxed) are shown. The sequence of the
antiporter motif or motif C is written for comparison, where X can be any amino acid. Residues conserved in all the MFS transporters that are
part of the motif are highlighted in gray, whereas residues conserved only in fungal MFS that were found critical for the activity are highlighted
in black.
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methods: microdilution assay and spot assay. Based on the
drug sensitivity results of these two methods and the loca-
tion of the residues inside or outside the conserved motif,
mutant variants could be placed into four categories. The
first category had four residues, G244, G251, G255, and
G259, which are also part of the motif C, and their replace-
ment by alanine (G244A, G251A, G255A, and G259A) led
to variable enhanced sensitivity to tested drugs (Fig. 5 A and
Table 1). For example, variants G244A, G251A, and G255A
were only partly sensitive to FLC, CER, and MTX but, in
comparison, were more sensitive toward CYH and 4-NQO.
The variant G259A, however, showed only a slight change in
sensitivity toward all the tested drugs (Fig. 5). Interestingly,
all four glycines of the first category, when substituted with
leucine (G244L, G251L, G255L, and G259L), showed more
drastic results, as can be seen by complete abrogation of
growth in the presence of the same concentration of the
drugs (Fig. 5B and Table 1). The residues which are con-
served and part of a motif, such as P260, and those which
were not part of a motif, such as L245, W248, P256, and
F262, were included in second category. The replacement of
these residues with alanine only resulted in a more dramatic
increase in drug susceptibility and showed almost no growth
in the presence of tested drugs (Fig. 5C). The third category,
which has one residue, G263, and is a part of the conserved
motif, showed no major change in drug susceptibility levels
when replaced with alanine (G263A) or leucine (G263L)
(Fig. 5D). All 11 residues of TMS 5 belonging to the fourth
category, when replaced with alanine (V243A, A246G,
A247G, S249A, L250A, A252G, V253A, C254A, S257A,
F258A, and F261A), did not affect the drug resistance pro-
file (Table 1). Considering that the residues of fourth cate-
gory were nonconserved and also not part of antiporter
motif, these residues were not replaced with other amino
acids, such as leucine. Thus, out of the 21 residues of TMS
5, substitution of only nine residues, namely G244, L245,
FIG. 5. Drug resistance profile of wild-type and mutant CaMDR1 strains determined by the spot assay. Cells were freshly streaked, grown
overnight, and then resuspended in normal saline to an A600 of 0.1. For spot assay, 5 l of fivefold serial dilutions, namely 1 (1:5), 2 (1:25), 3 (1:125),
and 4 (1:625), of each strain was spotted on to YEPD plates in the absence (control) and presence of the following drugs: FLC (0.17 g/ml), CYH
(0.2 g/ml), CER (3 g/ml), 4-NQO (0.2 g/ml), and MTX (65 g/ml). Growth differences were recorded following incubation of the plates for
48 h at 30°C. Growth was not affected by the presence of the solvents used for the drugs (data not shown). Panels A and B show the mutant variants
of first category of mutant variants substituted with alanine and leucine, respectively. (C) Second category of mutant variants substituted with
alanine only. (D) Third category of mutant variants substituted with both alanine and leucine.
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W248, G251, G255, P256 G259, P260, and F262, affected
drug susceptibilities to various degrees (Fig. 5A, B, and C
and Table 1). The drug sensitivities revealed by spot assays
matched well with the microdilution results (see Table S3 in
the supplemental material).
To exclude the possibility that the observed hypersuscepti-
bility of the mutant variants was not due to poor expression or
impaired surface localization, we compared the protein local-
ization of RPCaMdr1p-GFP and mutant variants by Western
blot analysis, FACS, and confocal microscopy. Western blot
analysis with anti-GFP antibody confirmed similar expression
levels of the mutants and the wild type (Fig. 6A). FACS and
confocal images also confirmed that there was no difference in
cell surface localization of CaMdr1-GFP between the cells
expressing wild-type and mutant variants (Fig. 6B).
Mutant variants display different levels of accumulation
(efflux) of radiolabeled drugs. All the mutants were further
analyzed for their functionality by measuring the intracellu-
lar accumulation of [3H]MTX and [3H]FLC. The first cate-
gory of mutant variants, when replaced by alanine, G244A,
G251A, G255A, and G259A, showed increased accumula-
tion of [3H]MTX and [3H]FLC (impaired efflux) (Fig. 7A and
B and Table 1). Similar to drug sensitivity results, the replace-
ment of glycines of the first category with leucine (G244L,
G251L, G255L, and G259L) resulted in a further increase in
accumulation of [3H]MTX and [3H]FLC (Fig. 7A and B and
Table 1). The mutant variants of the second category, including
L245A, W248A, P256A, P260A, and F262A, also showed in-
creases in their ability to accumulate [3H]MTX and [3H]FLC,
thus implying decreased efflux of drugs (Fig. 7A and B and
Table 1). The third category mutant variant G263, whether
replaced with alanine or leucine, had no major impact on drug
resistance profile and displayed unaltered accumulation of
[3H]MTX and [3H]FLC, comparable to cells expressing wild-
type protein (Fig. 7A and B and Table 1).
The mutant variants of the fourth category (V243A, A246G,
A247G, S249A, L250A, A252G, V253A, C254A, S257A,
F258A, and F261A), which showed no change in the drug
resistance profile, also did not display any change in the level
of accumulation of the drugs (data not shown). Of note, the
reduced ability to efflux drug matched well with the drug sus-
ceptibility data for all the categories (Fig. 5 and 7).
TMS 5 and substrate binding and transport. The mutant
variants which displayed sensitivity in the drug susceptibility
assays and were defective in transport were also checked for
substrate binding. To examine the effect of TMS 5 mutations
on the drug binding sites or ion coupling and transport,
[3H]MTX accumulation was competed with fivefold molar
excesses of different drugs. The accumulation of [3H]MTX
could only be competed out by a molar excess of MTX and
4-NQO, while other tested drugs could not affect the accu-
mulation in wild-type RPCaMDR1-GFP cells (Fig. 8A). It
TABLE 1. Summarized representations of the mutant variantsa
Category Residuesubstitution
Drug susceptibility Drug accumulation(relative %) Position
FLC CYH 4-NQO CER MTX FLC MTX
AD1-8u      100 100
RPCaMdr1p-GFP      31 34
One G244A      55 54 Inside
G251A      54 54 Inside
G255A      60 54 Inside
G259A      56 54 Inside
G244L      72 80 Inside
G251L      77 77 Inside
G255L      87 86 Inside
G259L      92 69 Inside
Two L245A      99 94 Outside
W248A      85 91 Outside
P256A      83 89 Outside
P260A      98 94 Inside
F262A      85 80 Outside
Three G263A      35 34 Inside
G263L      39 37 Inside
Four V243A      No change No change Outside
A246G      Outside
A247G      Outside
S249A      Outside
L250A      Outside
A252G      Outside
V253A      Outside
C254A      Outside
S257A      Outside
F258A      Outside
F261A      Outside
a The drug susceptibility column shows the degree of growth on all of the tested drugs, as follows: , hyperresistant cells; , moderately resistant; ,
slightly resistant; , slight growth; , hypersensitive variants, with no growth at all. The drug accumulation column shows the relative percent accumulation of the two
drugs, [3H]FLC and [3H]MTX. The results are shown as relative percentages with respect to drug accumulation of host strain AD1-8u taken as 100%. The position
column indicates the position of the variant inside or outside the motif C or antiporter motif.
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FIG. 6. Comparison of expression of RPCaMDR1p-GFP and different mutant variant localization. (A) Western blot analyses of the PM fractions of mutant
variants, with anti-GFP antibody, to confirm their proper targeting. (B) Confocal images and FACS analyses of the mutants of first, second, and third categories
to check their expression, proper folding, and localization and comparison with AD1-8u (negative control) and RPCaMDR1-GFP (positive control).
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means that MTX and 4-NQO share a common substrate
binding site(s). R6G is not a substrate of CaMdr1p-GFP
and, expectedly, was unable to affect the accumulation of
[3H]MTX (Fig. 8A). Similar to native CaMdr1p-GFP, the
accumulation of [3H]MTX by the first category of mutants,
G244A, G251A, G255A, and G259A, could be competed out
with MTX and 4-NQO, suggesting that these residues are
not directly involved in drug transport (Fig. 8B). However,
when glycines of the first category were replaced with
leucine (G244L, G251L, G255L, and G259L), both MTX
and 4-NQO could not compete with the accumulation of
[3H]MTX (Fig. 8C). Of note, as a result of substitution of
conserved glycines with leucine, the accumulation of [3H]MTX
was severely reduced in these variants, and hence, a clear
distinction between the inability of MTX and 4-NQO to com-
pete with [3H]MTX and the mutant variants’ inability to par-
ticipate in drug/H transport could not be made. However,
based on the fact that the efflux properties do not change after
replacement of conserved glycines with alanine, one could cau-
tiously state that these residues may not be directly involved in
MTX binding and transport.
As shown in Fig. 8D, the accumulation of [3H]MTX could
not be competed out by any drug in the five mutant variants of
second category, namely L245A, W248A, P256A, P260A, and
F262A. The mutant variant of the third category, G263, be-
haved as wild-type protein whether replaced with alanine
(G263A) or leucine (G263L) (Fig. 8E).
DISCUSSION
CaMdr1p is one of the major efflux pumps of C. albicans
belonging to the MFS which is involved in clinically encoun-
tered azole resistance. CaMdr1p is functionally identical to
ABC drug transporters such as Cdr1p and Cdr2p; however,
they differ with regard to the mechanisms of drug extrusion.
While the MFS CaMdr1p is a putative antiporter that ex-
changes H with antifungal compounds, the ABC transporters
such as Cdr1p and Cdr2p accomplish drug efflux by coupling it
directly to the hydrolysis of ATP. Our studies confirmed that
an overexpression of CaMDR1-GFP in a heterologous system
confers resistance to a variety of tested drugs because of its
ability to expel these substrates. The efflux of drug substrates
such as MTX and FLC is sensitive to pH, which could be
blocked by a proton dissipater like CCCP, confirming that the
electrochemical gradient of protons is utilized to extrude the
drugs.
The characteristic and well-conserved antiporter motif in
TMS 5 was found to be essential for the functionality of
CaMdr1p, which was evident from the fact that not even a
single substitution of conserved residue within the motif is
functionally compensated. Interestingly, all the amino acid
residues of CaMdr1p whose substitution resulted in en-
hanced drug susceptibility and abrogated efflux are clustered
in a helical wheel projection of TMS 5 (Fig. 9). The clus-
tering of mutation-sensitive residues on the same face of the
helix further confirms that these residues are important for
the structural and functional role of the transporter protein
(Fig. 9). Importantly, we observed that residues such as
W248 and F262 of CaMdr1p, typical of fungal MFS trans-
porters, were critical for enzymatic activity. Previous studies
have shown that the aromatic amino acids, such as Phe, Tyr,
and Trp, are involved in cationic-
 interaction, where aro-
matic side chains bind to the cations in the aqueous media
to pull it out from the water molecule into a hydrophobic
FIG. 7. [3H]MTX and [3H]FLC accumulation in the different mutant variants. [3H]MTX (A) and [3H]FLC (B) accumulation in the first,
second, and third categories of mutant variants. The first and third categories of five glycines of antiporter motif substituted with leucine are also
shown as black bars for better comparison of glycines substituted with alanine. Controls AD1-8u and RPCaMDR1-GFP are also included for
comparison. The results are the means 	 standard deviations from three independent experiments.
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environment, to possibly help in the generation of proton
gradient (3). This observation is important because gener-
ally negatively charged residues are involved in proton-cou-
pled translocation, but recent reports of MdfA, transporter
of E. coli, have shown that different MFS transporters might
utilize different proton recognition strategies (23). It is thus
probable that aromatic amino acids W248 and F262 of
CaMdr1p and of other fungal MFS transporters may also lie
in the glycine-rich pocket and help in utilizing proton gra-
dient. The significance of W248 and F262 in CaMdr1p re-
quires further evaluation.
Interestingly, on one hand, both FLC and MTX could be
extruded by the transporter but were unable to compete for
each other, thus implying that these two drug substrates share
different binding sites. This selectivity between the two sub-
strates was retained by all the mutant variants which were
capable of extruding MTX. Our competition results further
suggest that at least conserved glycines of the core antiporter
motif do not appear to affect drug binding to CaMdr1p. Thus,
observed impairment in efflux by conserved glycine replace-
ment with alanine and the fact that, similar to wild-type pro-
tein, MTX and 4-NQO could compete with [3H]MTX efflux
mediated by these variants suggest that these conserved motif
residues do not directly participate in drug binding. The im-
pairment in drug efflux is probably because of the mutant
variant’s inability to participate in drug/H transport. This
issue can, however, be resolved only by direct drug binding
studies by employing radio- and photoaffinity-labeled drug sub-
strates.
Taken together, our study supports the prediction that
MFS CaMdr1p of C. albicans functions as a drug/H anti-
porter. The high degree of conservation in TMS 5, along
with mutational data, strongly confirms that the motif
G(X6)G(X3)G(X3)GP(X2)G is essential for drug/H
 trans-
FIG. 8. Competition of various drugs with [3H]MTX for common substrate binding sites. For competition between [3H]MTX and various drugs,
[3H]MTX was used at a final concentration of 25 M, and a fivefold concentration of each drug (125 M), MTX, FLC, CYH, 4-NQO, and
rhodamine 6G (R6G), was used for competition studies. (A) Comparison of the control strains AD1-8u (negative) and RPCaMdr1p-GFP
(positive). MTX and 4-NQO compete for the [3H]MTX in RPCaMdr1p-GFP. Panels B and C show the first category of the mutant variants, either
substituted with alanine or leucine, respectively. (D) Second category of the mutant variants, showing drastic increase in accumulation, implying
reduced efflux. (E) Third category of mutant which remained unaffected whether substituted with alanine or leucine. The results are the means
from three independent experiments and are represented in pmol/mg (dry weight). The values are derived from the accumulation.
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port. The placements of critical residues which are typical to
this fungal transporter do suggest structural and functional
differences among MFS drug transporters.
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FIG. 9. A helical wheel projection of the primary amino acid se-
quence was constructed using 3.6 amino acids per turn of the helix by
the EMBOSS PEPWHEEL program (17). Mutations that affected the
functionality of the CaMdr1p are numbered and highlighted in black.
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